Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
January 13, 2017
– First-in-class orally active prostaglandin F2α receptor antagonist designed to safely control inflammation, uterine contractions, membrane ruptures and cervical changes that…
Read morepress release
October 24, 2016
Trial shows meaningful increase in pregnancy and live birth rates in patients treated with OBE001 ObsEva to proceed with a…
Read morepress release
October 17, 2016
GENEVA, SWITZERLAND, 17 October, 2016 – ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel…
Read moreJune 29, 2023
May 18, 2022
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840